stoxline Quote Chart Rank Option Currency Glossary
  
Novavax, Inc. (NVAX)
7.995  -0.255 (-3.09%)    02-19 12:48
Open: 8.16
High: 8.1953
Volume: 1,791,453
  
Pre. Close: 8.25
Low: 7.91
Market Cap: 1,281(M)
Technical analysis
2025-02-19 12:21:18 PM
Short term     
Mid term     
Targets 6-month :  10.53 1-year :  11.44
Resists First :  9.01 Second :  9.8
Pivot price 8.34
Supports First :  7.75 Second :  6.44
MAs MA(5) :  8.09 MA(20) :  8.57
MA(100) :  9.46 MA(250) :  9.97
MACD MACD :  -0.3 Signal :  -0.2
%K %D K(14,3) :  19.9 D(3) :  19
RSI RSI(14): 41.7
52-week High :  23.86 Low :  3.8
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NVAX ] has closed above bottom band by 23.0%. Bollinger Bands are 50.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.55 - 8.59 8.59 - 8.62
Low: 8.13 - 8.17 8.17 - 8.2
Close: 8.19 - 8.25 8.25 - 8.32
Company Description

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Headline News

Tue, 04 Feb 2025
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Mon, 20 Jan 2025
Novavax, Inc. (NVAX) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025 - Yahoo Finance

Thu, 09 Jan 2025
Why Novavax Stock Is Volatile This Week - Benzinga

Wed, 08 Jan 2025
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Thu, 12 Dec 2024
Institutional investors control 53% of Novavax, Inc. (NASDAQ:NVAX) and were rewarded last week after stock increased 6.3% - Yahoo Finance

Tue, 10 Dec 2024
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 160 (M)
Shares Float 142 (M)
Held by Insiders 8.7 (%)
Held by Institutions 60.4 (%)
Shares Short 34,940 (K)
Shares Short P.Month 36,920 (K)
Stock Financials
EPS -2.19
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -3.29
Profit Margin -32.2 %
Operating Margin -153.7 %
Return on Assets (ttm) -10.8 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth -54.8 %
Gross Profit (p.s.) 0.72
Sales Per Share 5.52
EBITDA (p.s.) -1.52
Qtrly Earnings Growth 0 %
Operating Cash Flow -91 (M)
Levered Free Cash Flow -247 (M)
Stock Valuations
PE Ratio -3.68
PEG Ratio 0
Price to Book value -2.44
Price to Sales 1.44
Price to Cash Flow -14.11
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android